tiprankstipranks
Trending News
More News >
Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
US Market

Belite Bio, Inc. ADR (BLTE) Earnings Dates, Call Summary & Reports

Compare
35 Followers

Earnings Data

Report Date
Aug 06, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
-0.39
Last Year’s EPS
-0.31
Same Quarter Last Year
Based on 5 Analysts Ratings

Earnings Call Summary

Earnings Call Date:May 14, 2025
|
% Change Since: 6.45%
|
Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook for Belite Bio, with significant progress in clinical trials for Tinlarebant and a robust financial position. However, increased operating expenses and pending regulatory details introduce some uncertainty.
Company Guidance
During the Belite Bio First Quarter 2025 Earnings Call, the company provided several key metrics and updates regarding their clinical trials and financial standing. In the Stargardt disease program, the Phase 3 DRAGON trial, involving 104 subjects, has moved forward successfully with the Data Safety Monitoring Board (DSMB) recommending no changes to the trial size and suggesting data submission for regulatory review. The DRAGON 2 trial has enrolled 16 out of a targeted 60 subjects. For geographic atrophy, the Phase 3 PHOENIX trial has enrolled 464 subjects out of a planned 500, with full enrollment expected by Q3 2025. Financially, the company reported R&D expenses of $9.4 million and G&A expenses of $6.1 million for Q1 2025, resulting in a net loss of $14.3 million. Despite the increased expenses, primarily due to share-based compensation, Belite Bio maintains a strong financial position with $157.4 million in cash and equivalents, ensuring a cash runway to complete current clinical trials.
Promising Clinical Progress for Tinlarebant
The Phase 3 DRAGON trial for Tinlarebant showed promising interim results with the DSMB recommending submission for further regulatory review. The trial is on track for completion by the end of the year.
Strong Financial Position
Belite Bio reported a cash increase of $12.3 million for the quarter, leaving the company with $157.4 million in cash and equivalents. The company expects a full year cash runway to complete all current clinical trials.
Phase 3 PHOENIX Trial Advancements
The PHOENIX trial for geographic atrophy has enrolled 464 subjects with a total target of 500. Enrollment is expected to be completed in Q3 2025.
Low Withdrawal Rates in Clinical Trials
DRAGON trial showed less than a 10% overall withdrawal rate, and the PHOENIX trial's dropout rate is approximately 20%, which is lower than comparables.

Belite Bio, Inc. ADR (BLTE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

BLTE Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 06, 2025
2025 (Q2)
-0.39 / -
-0.31
May 14, 2025
2025 (Q1)
-0.35 / -0.45
-0.27-66.67% (-0.18)
Mar 17, 2025
2024 (Q4)
-0.31 / -0.32
-0.25-28.00% (-0.07)
Nov 12, 2024
2024 (Q3)
-0.29 / -0.28
-0.430.00% (+0.12)
Aug 09, 2024
2024 (Q2)
-0.26 / -0.31
-0.26-19.23% (-0.05)
May 14, 2024
2024 (Q1)
-0.28 / -0.27
-0.3318.18% (+0.06)
Mar 12, 2024
2023 (Q4)
-0.30 / -0.25
-0.3732.43% (+0.12)
Nov 14, 2023
2023 (Q3)
-0.32 / -0.40
-0.11-263.64% (-0.29)
Aug 09, 2023
2023 (Q2)
-0.30 / -0.26
-0.08-225.00% (-0.18)
May 10, 2023
2023 (Q1)
- / -
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

BLTE Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 14, 2025
$60.89$61.60+1.17%
Mar 17, 2025
$67.44$67.81+0.55%
Nov 12, 2024
$78.64$81.15+3.19%
Aug 09, 2024
$49.48$48.55-1.88%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Belite Bio, Inc. ADR (BLTE) report earnings?
Belite Bio, Inc. ADR (BLTE) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
    What is Belite Bio, Inc. ADR (BLTE) earnings time?
    Belite Bio, Inc. ADR (BLTE) earnings time is at Aug 06, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is BLTE EPS forecast?
          BLTE EPS forecast for the fiscal quarter 2025 (Q2) is -0.39.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis